William Pao

William Pao is the founder of Revelio Therapeutics, Inc., founded in 2024, where he holds the title of Chief Executive Officer.
Dr. Pao is also the founder of My Cancer Genome.
Current jobs include Director at Transcelerate Biopharma, Inc., Director at Obsidian Therapeutics, Inc., Director at Alentis Therapeutics AG, and Independent Non-Executive Director at Immunocore Holdings Plc starting in 2025.
Former jobs include Professor and Director of the Hematology & Oncology Division at Vanderbilt University, Director at the American Association for Cancer Research, Director of Personalized Cancer Medicine at The Vanderbilt-Ingram Cancer Center, Chief Development Officer and Executive Vice President at Pfizer Inc. from 2022 to 2023, and Head of Pharma Research & Early Development at Roche Holding AG and F.
Hoffmann-La Roche Ltd. from 2014 to 2022.
Education includes undergraduate studies at Harvard University and a doctorate from Yale University.